国际医药卫生导报2016，Vol.22Issue(21)：3245-3247,3.DOI:10.3760/cma.j.issn.1007-1245.2016.21.010
康艾注射液联合美罗华治疗恶性淋巴瘤的临床疗效及安全性研究
Clinical efficacy and safety of Kang'ai injection combined with rituximab in the treatment of malignant lymphoma
摘要
Abstract
Objective To investigate the clinical efficacy and safety of Kang'ai injection combined with rituximab in the treatment of malignant lymphoma.Methods 82 patients with malignant lymphoma in our hospital from June 2014 to June 2015 were selected as study subjects.Control group only received rituximab treatment,observation group was given Kang'ai injection on the basis of control group.Compared the treatment effect,observed the incidence of adverse reactions,detected the levels of neuron specific enolase (NSE),cytokeratin 19 fragment (CYFRA21-1),and malignant tumor specific growth factor (TSGF) before and after treatment.Results After treatment,CR rate,PR rate and the total effective rate of observation group were 51.2％,36.6％,and 87.8％ respectively,significantly higher than those of control group,PD rate was 0％,significantly lower than that of control group.There were no serious adverse reactions in all patients during treatment.NSE,CYFRA21-1,and TSGF significantly improved after treatment in observation group.Conclusion Kang'ai injection combined with rituximab in the treatment of malignant lymphoma can effectively improve the therapeutic effect,with good security,worthy of further study.关键词
康艾注射液/美罗华/恶性淋巴瘤Key words
Kang'ai injection/Rituximab/Malignant lymphoma引用本文复制引用
潘清文,陈哲,罗俭权,陈达勇..康艾注射液联合美罗华治疗恶性淋巴瘤的临床疗效及安全性研究[J].国际医药卫生导报,2016,22(21):3245-3247,3.
